Results 21 to 30 of about 327,289 (308)

Advances in Human Immune System Mouse Models for Personalized Treg-Based Immunotherapies

Frontiers in Immunology, 2021
Immunodeficient mice engrafted with a functional human immune system [Human immune system (HIS) mice] have paved the way to major advances for personalized medicine and translation of immune-based therapies.
Isabelle Serr, Isabelle Serr, Maria Kral, Maria Kral, Martin G. Scherm, Martin G. Scherm, Carolin Daniel, Carolin Daniel, Carolin Daniel   +8 more
doaj   +1 more source

Challenges and Opportunities for Biomarkers of Clinical Response to AHSCT in Autoimmunity

Frontiers in Immunology, 2018
Autoimmunity represents a broad category of diseases that involve a variety of organ targets and distinct autoantigens. For patients with autoimmune diseases who fail to respond to approved disease-modifying treatments, autologous hematopoietic stem cell
Kristina M. Harris, Tingting Lu, Noha Lim, Laurence A. Turka, Laurence A. Turka   +4 more
doaj   +1 more source

Interleukin-5 Mediates Parasite-Induced Protection against Experimental Autoimmune Encephalomyelitis: Association with Induction of Antigen-Specific CD4+CD25+ T Regulatory Cells

Frontiers in Immunology, 2017
ObjectiveTo examine if the protective effect of parasite infection on experimental autoimmune encephalomyelitis (EAE) was due to interleukin (IL)-5, a cytokine produced by a type-2 response that induces eosinophilia.
Giang T. Tran, Paul L. Wilcox, Lindsay A. Dent, Catherine M. Robinson, Nicole Carter, Nirupama D. Verma, Bruce M. Hall, Suzanne J. Hodgkinson   +7 more
doaj   +1 more source

Incubation of Immune Cell Grafts With MAX.16H5 IgG1 Anti-Human CD4 Antibody Prolonged Survival After Hematopoietic Stem Cell Transplantation in a Mouse Model for Fms Like Tyrosine Kinase 3 Positive Acute Myeloid Leukemia

Frontiers in Immunology, 2018
Despite the constant development of innovative therapeutic options for hematological malignancies, the gold-standard therapy regimen for curative treatment often includes allogeneic hematopoietic stem cell transplantation (HSCT).
Nadja Hilger, Nadja Hilger, Claudia Mueller, Lilly Stahl, Anne M. Mueller, Bianca Zoennchen, Sarah Dluczek, Christoph Halbich, Claudia Wickenhauser, Dennis Gerloff, Alexander A. Wurm, Gerhard Behre, Anna Kretschmer, Stephan Fricke   +13 more
doaj   +1 more source

The Epitope-Specific Anti-human CD4 Antibody MAX.16H5 and Its Role in Immune Tolerance

Frontiers in Immunology, 2019
T cell modulation in the clinical background of autoimmune diseases or allogeneic cell and organ transplantations with concurrent preservation of their natural immunological functions (e.g., pathogen defense) is the major obstacle in immunology.
Lilly Stahl, Anna Duenkel, Nadja Hilger, Uta Sandy Tretbar, Stephan Fricke   +4 more
doaj   +1 more source

Changes in Reactivity In Vitro of CD4+CD25+ and CD4+CD25− T Cell Subsets in Transplant Tolerance

Frontiers in Immunology, 2017
Transplant tolerance induced in adult animals is mediated by alloantigen-specific CD4+CD25+ T cells, yet in many models, proliferation of CD4+ T cells from hosts tolerant to specific-alloantigen in vitro is not impaired.
Bruce M. Hall, Catherine M. Robinson, Karren M. Plain, Karren M. Plain, Nirupama D. Verma, Giang T. Tran, Masaru Nomura, Masaru Nomura, Nicole Carter, Nicole Carter, Rochelle Boyd, Rochelle Boyd, Suzanne J. Hodgkinson   +12 more
doaj   +1 more source

Loss of Zbtb32 in NOD mice does not significantly alter T cell responses. [version 2; referees: 2 approved]

F1000Research, 2018
Background: We previously identified the transcriptional regulator Zbtb32 as a factor that can promote T cell tolerance in the Non-Obese Diabetic (NOD) mouse, a model of Type 1 diabetes.
William D. Coley, Yongge Zhao, Charles J. Benck, Yi Liu, Chie Hotta-Iwamura, M. Jubayer Rahman, Kristin V Tarbell   +6 more
doaj   +1 more source

Loss of Zbtb32 in NOD mice does not significantly alter T cell responses. [version 1; referees: 2 approved]

F1000Research, 2018
Background: We previously identified the transcriptional regulator Zbtb32 as a factor that can promote T cell tolerance in the Non-Obese Diabetic (NOD) mouse, a model of Type 1 diabetes.
William D. Coley, Yongge Zhao, Charles J. Benck, Yi Liu, Chie Hotta-Iwamura, M. Jubayer Rahman, Kristin V Tarbell   +6 more
doaj   +1 more source

Advancements in immune tolerance [PDF]

Advanced Drug Delivery Reviews, 2008
In recent years, considerable attention has been given to immune tolerance and its potential clinical applications for the treatment of cancers and autoimmune diseases, and the prevention of allo-graft rejection and graft-versus-host diseases. Advances in our understanding of the underlying mechanisms of establishment and maintenance of immune ...
Ping-Ying, Pan, Junko, Ozao, Zuping, Zhou, Shu-Hsia, Chen   +3 more
openaire   +2 more sources

Beta cell and immune cell interactions in autoimmune type 1 diabetes: How they meet and talk to each other

Molecular Metabolism, 2022
Background: The highly complex pathogenesis of Type 1 Diabetes is driven by several immune cell types with both effector and regulatory characteristics, which ultimately ends in the destruction of the insulin-producing beta cells.
Martin G. Scherm, Rebecca C. Wyatt, Isabelle Serr, David Anz, Sarah J. Richardson, Carolin Daniel   +5 more
doaj   +1 more source